

**WHAT IS CLAIMED IS:**

1. A compound of Formula I:

5 A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is  $-\text{NH}-\text{C}(\text{O})-\text{NH}-$ ,

A is a substituted moiety of up to 40 carbon atoms of the formula:  $-L-(M-L^1)_q$ , where L is a 5 or 6 membered cyclic structure bound directly to D,  $L^1$  comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and  $L^1$  contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,

wherein  $L^1$  is substituted by at least one substituent selected from the group consisting of  $-SO_2R_x$ ,  $-C(O)R_x$  and  $-C(NR_y)R_z$ ,

$R_y$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to 20 per halo,

$R_z$  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

25  $R_x$  is  $R_z$  or  $NR_aR_b$  where  $R_a$  and  $R_b$  are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

5 -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

10 b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

15 c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected

20 from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W<sub>n</sub>, where n is 0-3;

25 wherein each W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and

halogen up to per-halo; with each R<sup>7</sup> independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -  
5 (CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-,  
where m= 1-3, and X<sup>a</sup> is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z  
10 is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>,  
15 -NR<sup>7</sup>C(O)R<sup>7</sup>, and -NR<sup>7</sup>C(O)OR<sup>7</sup>, with R<sup>7</sup> as defined above.

2. A compound as in claim 1 wherein:

R<sub>y</sub> is hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted C<sub>6-C<sub>14</sub></sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C<sub>7-24</sub> alkaryl or substituted C<sub>7-C<sub>24</sub></sub> aralkyl, where R<sub>y</sub> is a substituted group, it is substituted by halogen up to per halo,

25

R<sub>z</sub> is hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatom, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-C<sub>12</sub></sub> hetaryl having 1-3 heteroatoms selected from, S, N and O, C<sub>7-24</sub> alkaryl, C<sub>7-24</sub> aralkyl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>6-C<sub>14</sub></sub> aryl, substituted C<sub>3-C<sub>10</sub></sub> cycloalkyl having 0-3 heteroatoms

selected from S, N and O, substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from S, N and O, substituted  $C_{7-24}$  alkaryl or substituted  $C_7-C_{24}$  aralkyl where  $R_2$  is a substituted group, it is substituted by halogen up to per halo, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_{1-6}$  halo substituted alkyl up to per halo alkyl,  $C_6-C_{12}$  halo substituted aryl up to per halo aryl,  $C_3-C_{12}$  halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted  $C_3-C_{12}$  hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted  $C_7-C_{24}$  aralkyl up to per halo aralkyl, halo substituted  $C_7-C_{24}$  alkaryl up to per halo alkaryl, and  $-C(O)R_g$ ,

$R_a$  and  $R_b$  are,

a) independently hydrogen,

a carbon based moiety selected from the group consisting of  $C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from O, N and S,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms selected from N, S and O,  $C_7-C_{24}$  aralkyl,  $C_7-C_{24}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy, substituted  $C_{3-10}$  cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted  $C_{6-12}$  aryl, substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O, substituted  $C_7-C_{24}$  aralkyl, substituted  $C_7-C_{24}$  alkaryl, where  $R_a$  and  $R_b$  are a substituted group, they are substituted by halogen up to per halo, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_{1-6}$  halo substituted alkyl up to per halo alkyl,  $C_6-C_{12}$  halo substituted aryl up to per halo aryl,  $C_3-C_{12}$  halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted  $C_3-C_{12}$  hetaryl up to per halo hetaryl, halo substituted  $C_7-C_{24}$  aralkyl up to per halo aralkyl, halo substituted  $C_7-C_{24}$  alkaryl up to per halo alkaryl, and  $-C(O)R_g$ ; or

$-OSi(R_f)_3$  where  $R_f$  is hydrogen,  $C_{1-10}$  alkyl,  $C_{1-10}$  alkoxy,  $C_3-C_{10}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl

having 1-3 heteroatoms selected from O, S and N, C<sub>7-24</sub> aralkyl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-C<sub>10</sub></sub> alkoxy, substituted C<sub>3-C<sub>12</sub></sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, substituted C<sub>3-C<sub>12</sub></sub> heteraryl having 1-3 heteroatoms selected from O, S, and N, substituted C<sub>6-12</sub> aryl, and substituted C<sub>7-24</sub> alkaryl, where R<sub>f</sub> is a substituted group

5 it is substituted halogen up to per halo, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-C<sub>12</sub></sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>3-C<sub>12</sub></sub> hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>7-C<sub>24</sub></sub> alkaryl, C<sub>7-C<sub>24</sub></sub> aralkyl, C<sub>1-6</sub> halo substituted alkyl up to per halo alkyl, C<sub>6-C<sub>12</sub></sub> halo substituted aryl up to per halo aryl, C<sub>3-C<sub>12</sub></sub> halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per halo heteraryl, halo substituted C<sub>7-C<sub>24</sub></sub> aralkyl up to per halo aralkyl, halo substituted C<sub>7-C<sub>24</sub></sub> alkaryl up to per halo alkaryl, and -C(O)R<sub>g</sub>,

10

or

b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O with substituents selected from the group consisting of halogen up to per halo, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-C<sub>12</sub></sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>3-C<sub>12</sub></sub> hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>7-C<sub>24</sub></sub> alkaryl, C<sub>7-C<sub>24</sub></sub> aralkyl, halo substituted C<sub>1-6</sub> alkyl up to per halo alkyl, halo substituted C<sub>6-C<sub>12</sub></sub> aryl up to per halo aryl, halo substituted C<sub>3-C<sub>12</sub></sub> cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per halo heteraryl, halo substituted C<sub>7-C<sub>24</sub></sub> aralkyl up to per halo aralkyl, halo substituted C<sub>7-C<sub>24</sub></sub> alkaryl up to per halo alkaryl, and -C(O)R<sub>g</sub>,

15

20

25

or

c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1-C<sub>5</sub></sub> divalent alkylene group or a substituted C<sub>1-C<sub>5</sub></sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members,

wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>1-6</sub> halo substituted alkyl up to per halo alkyl, C<sub>6</sub>-C<sub>12</sub> halo substituted aryl up to per halo aryl, C<sub>3</sub>-C<sub>12</sub> halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per halo heteraryl, halo substituted C<sub>7</sub>-C<sub>24</sub> aralkyl up to per halo aralkyl, halo substituted C<sub>7</sub>-C<sub>24</sub> alkaryl up to per halo alkaryl, and -C(O)R<sub>g</sub>,

10 where R<sub>g</sub> is C<sub>1-10</sub> alkyl; -CN, -CO<sub>2</sub>R<sub>d</sub>, -OR<sub>d</sub>, -SR<sub>d</sub>, -NO<sub>2</sub>, -C(O)R<sub>e</sub>, -NR<sub>d</sub>R<sub>e</sub>, -NR<sub>d</sub>C(O)OR<sub>e</sub> and -NR<sub>d</sub>C(O)R<sub>e</sub>, and R<sub>d</sub> and R<sub>e</sub> are independently selected from the group consisting of hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, C<sub>6-12</sub> aryl, C<sub>3</sub>-C<sub>12</sub> hetaryl with 1-3 heteroatoms selected from O, N and S and C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>7</sub>-C<sub>24</sub> alkaryl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per halo substituted C<sub>3</sub>-C<sub>12</sub> hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C<sub>7</sub>-C<sub>24</sub> alkaryl up to per halo alkaryl, and up to per halo substituted C<sub>7</sub>-C<sub>24</sub> aralkyl,

20

W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>3</sub>-C<sub>12</sub> heteraryl having 1-3 heteroatoms selected from O, N and S, C<sub>4</sub>-C<sub>23</sub> alkoheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>1</sub>-C<sub>10</sub> alkoxy, substituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted C<sub>1</sub>-C<sub>10</sub> alkenoyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C<sub>6</sub>-C<sub>12</sub> aryl, substituted C<sub>3</sub>-C<sub>12</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>4</sub>-C<sub>23</sub> alkoheteroaryl having 1-3 heteroatoms selected from O, N and S, and -Q-Ar;

R<sup>7</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, C<sub>7</sub>-C<sub>14</sub> alkaryl, 5 C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per-halosubstituted C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl, and up to 10 per-halosubstituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl; and

each Z is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1</sub>-C<sub>10</sub> 15 alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>1</sub>-C<sub>10</sub> alkoxy, substituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted C<sub>1</sub>-C<sub>10</sub> alkenoyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, 20 substituted C<sub>6</sub>-C<sub>12</sub> aryl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl and substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and -NR<sup>7</sup>C(O)OR<sup>7</sup>.

25

3. A compound as in claim 1 wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is as defined in claim 1.

4. A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

5. A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable 5 hydrogen and a pKa of 10 or less.

6. A compound of claim 1 wherein B of Formula I is a substituted or unsubstituted six member aryl moiety or six member hetaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the balance of the hetaryl moiety being carbon.

10 7. A compound of claim 1 wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in claim 1, a pyrimidinyl group substituted by a substituent selected from the group constituting of halogen and Wn, whereas W and n are 15 as defined in Claim 1, or a substituted pyridyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in claim 1.

20 8. A compound of claim 6 wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyridyl group substituted 1 to 3 times by 1 or more substituents selected from the group consisting of -CN, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, -OH, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy or phenyl substituted by halogen up to per halo.

25 9. A compound of claim 1, wherein L, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen and Wn wherein W and n are as defined in claim 1.

10. A compound of claim 8, wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.

11. A compound of claim 1, wherein said substituted cyclic moiety L<sup>1</sup> 5 comprises a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur.

12. A compound of claim 1, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

10 13. A compound of claim 3, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

14. A compound of claim 6, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

15 15. A compound of claim 8, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

16. A compound of claim 9, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

17. A compound of claim 10, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

20 18. A compound of claim 14, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

25 19. A compound of claim 15, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety

of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

20. A compound of claim 16, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

21. A compound of claim 17, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

22. A compound of claim 1 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

23. A compound of claim 13 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

24. A compound of claim 18 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

25. A compound of claim 19 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

26. A compound of claim 20 wherein  $L^1$  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of  $C_1$ - $C_{10}$  alkyl, up to per halo substituted  $C_1$ - $C_{10}$  alkyl, -CN, -OH, halogen,  $C_1$ - $C_{10}$  alkoxy and up to per halo substituted  $C_1$ - $C_{10}$  alkoxy.

5 27. A compound of claim 21 wherein  $L^1$  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of  $C_1$ - $C_{10}$  alkyl, up to per halo substituted  $C_1$ - $C_{10}$  alkyl, -CN, -OH, halogen,  $C_1$ - $C_{10}$  alkoxy and up to per halo substituted  $C_1$ - $C_{10}$  alkoxy.

10 28. A compound of claim 1 wherein  $L^1$  is substituted by  $-C(O)R_x$ .  
29. A compound of claim 1 wherein  $L^1$  is substituted by  $-SO_2R_x$ .  
30. A compound of claim 1 wherein  $L^1$  is substituted only by  $-C(O)R_x$ .  
31. A compound of claim 1 wherein  $L^1$  is substituted only by  $-SO_2R_x$ .  
32. A compound of claim 1 wherein  $L^1$  is substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$ .

15 33. A compound of claim 13 wherein  $L^1$  is substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$ , and  $R_a$  and  $R_b$  are

20 a) independently hydrogen,  
a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

25  $-OSi(R_f)_3$  where  $R_f$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b)  $R_a$  and  $R_b$  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy

or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

5 c) one of  $R_a$  or  $R_b$  is  $-C(O)-$ , a  $C_1$ - $C_5$  divalent alkylene group or a substituted  $C_1$ - $C_5$  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted  $C_1$ - $C_5$  divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

10 34. A compound of claim 18 wherein  $L^1$  is substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$  and  $R_a$  and  $R_b$  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

15 35. A compound of claim 19 wherein  $L^1$  is substituted by  $-C(O)R_x$ , wherein  $R_x$  is  $NR_aR_b$  and  $R_a$  and  $R_b$  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

20 36. A compound of claim 20 wherein  $L^1$  is substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$  and  $R_a$  and  $R_b$  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

25 37. A compound of claim 21 wherein  $L^1$  is substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$  and  $R_a$  and  $R_b$  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of

up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

38. A compound of Formula I:

5

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L<sup>1</sup>)<sub>q</sub>, where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly 10 to D, L<sup>1</sup> comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L<sup>1</sup> contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of 15 up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,

wherein L<sup>1</sup> is substituted by at least one substituent selected from the group consisting of -SO<sub>2</sub>R<sub>x</sub>, -C(O)R<sub>x</sub> and -C(NR<sub>y</sub>)R<sub>z</sub>,

R<sub>y</sub> is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally 20 containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

R<sub>z</sub> is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally 25 contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R<sub>x</sub> is R<sub>z</sub> or NR<sub>a</sub>R<sub>b</sub> where R<sub>a</sub> and R<sub>b</sub> are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy

and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

5 -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

10 b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

15 c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

20 where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W<sub>n</sub>, where n is 0-3;

25 wherein each W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and halogen up to per-halo; with each R<sup>7</sup> independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and -NR<sup>7</sup>C(O)OR<sup>7</sup>, with R<sup>7</sup> as defined above; and

wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen.

39. A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L<sup>1</sup>)<sub>q</sub>, where L is a substituted or unsubstituted phenyl or peritoneal moiety bound directly to D, L<sup>1</sup> comprises a substituted phenyl, peritoneal or pyrimidinyl moiety, M is a bridging group having at least one atom, q is an integer of from 1-3; and

B is a substituted or unsubstituted phenyl or pyridine group bound directly to D,

wherein L<sup>1</sup> is substituted by at least one substituent selected from the group consisting of -SO<sub>2</sub>R<sub>x</sub>, -C(O)R<sub>x</sub> and -C(NR<sub>y</sub>)R<sub>z</sub>,

R<sub>y</sub> is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and ;

R<sub>z</sub> is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R<sub>x</sub> is R<sub>z</sub> or NR<sub>a</sub>R<sub>b</sub> where R<sub>a</sub> and R<sub>b</sub> are

a) independently hydrogen,

10 a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

15 -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

20 b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

25 c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W<sub>n</sub>, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and halogen up to per-halo; with each R<sup>7</sup> independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and -NR<sup>7</sup>C(O)OR<sup>7</sup>; and

wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen.

40. A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

41. A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

42. A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by -OH.

43. A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.

44. A compound as in claim 38 wherein substituents for B and L and additional substituents for L<sup>1</sup>, are selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, CN, OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

45. A compound as in claim 39 wherein substituents for B and L and additional substituents for L<sup>1</sup>, are selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, CN, OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

46. A compound of claim 38 wherein L<sup>1</sup> is substituted by C(O)R<sub>x</sub> or SO<sub>2</sub>R<sub>x</sub>.

47. A compound of claim 39 wherein L<sup>1</sup> is substituted by C(O)R<sub>x</sub> or SO<sub>2</sub>R<sub>x</sub>.

48. A compound of claim 46 wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen..

49. A compound of claim 47 wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

50. A compound of claim 1 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, 5 methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

10 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

51. A compound of claim 2 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

15 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, 20 succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

25 52. A compound of claim 33 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene

sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

5           b)     acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

53.    A compound of claim 38 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

10           a)     basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

15           b)     acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

20    54.    A compound of claim 39 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

25           a)     basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

55. A pharmaceutical composition comprising a compound of claim 1 or a 5 pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

56. A pharmaceutical composition comprising a compound of claim 2 consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

10 57. A pharmaceutical composition comprising a compound of claim 33 consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

15 58. A pharmaceutical composition comprising a compound of claim 38 consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

59. A pharmaceutical composition comprising a compound of claim 39 consistent with formula I or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier.

60. A compound selected from the group consisting of  
20 3-tert butyl phenyl ureas of Table 1 above;  
5-tert butyl-2-methoxyphenyl ureas of Table 2 above;  
5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;  
3-(trifluoromethyl) -4 chlorophenyl ureas of Table 4 above;  
3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;  
25 5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and  
ureas 101-103 in Table 7 above.

61. A compound selected from the group consisting of  
the 3-*tert* butyl phenyl ureas:  
*N*-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl urea and  
*N*-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl urea;

5  
the 5-*tert*-butyl-2-methoxyphenyl ureas:  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-  
10 methylcarbamoyl)phenoxy)phenyl) urea and  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;

the 2-methoxy-5-(trifluoromethyl)phenyl ureas:  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl)  
15 urea,  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-  
pyridyloxy)phenyl) urea,  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl)  
urea,  
20 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-  
pyridyloxy)phenyl) urea,  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-  
pyridylthio)phenyl) urea,  
25 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-  
pyridyloxy))phenyl) urea and  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-  
pyridyloxy))phenyl) urea;

the 4-chloro-3-(trifluoromethyl)phenyl ureas:  
30 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea  
 and  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

### the 4-romo-3-(trifluoromethyl)phenyl ureas:

10 *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,  
15 *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy)phenyl) urea and  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy)phenyl) urea; and  
20 the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:  
*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
25 *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy)phenyl) urea and  
*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy)phenyl) urea.  
30 62. A method for the treatment of a cancerous cell growth mediated by kinase, comprising administering a compound of Formula I of claim 1.

63. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 33.

64. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 38.

5 65. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 39.

66. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administrating a compound selected from the group consisting of

3-*tert* butyl phenyl ureas of Table 1 above;

10 5-*tert* butyl-2-methoxyphenyl ureas of Table 2 above;

5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;

3-(trifluoromethyl)-4 chlorophenyl ureas of Table 4 above;

3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;

5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and

15 ureas 101-103 in Table 7 above.

67. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administrating a compound selected from the group consisting of the 3-*tert* butyl phenyl ureas:

*N*-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl urea and

20 *N*-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl urea;

the 5-*tert*-butyl-2-methoxyphenyl ureas:

*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,

*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,

25 *N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and

*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;

the 2-methoxy-5-(trifluoromethyl)phenyl ureas:

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

5 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-

10 pyridyloxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

15 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

20 *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

the 4-chloro-3-(trifluoromethyl)phenyl ureas:

25 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

30 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and

35 *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

the 4-romo-3-(trifluoromethyl)phenyl ureas:

40 *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-

30 pyridyloxy)phenyl) urea,

404762-0001

*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

5   *N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

10   the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

15   *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.